CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-404

Based on the current run rate of $28m, this is significantly undervalued. Peer companies trade at valuations of over 10x revenue during their growth stages, and as such over $1 would be a far more appropriate valuation for a company of this quality. Best in class device with a larger assortment of patents protecting its unique features, it's no wonder this is the fastest growing company in the MIGS space (and the closest to profitability).

The company said they expect a "material improvement" in the operating result due to the very strong growth, and so I suspect the results released within the next couple of weeks could be a major catalyst for a rerate event. The audited results will be picked up by the algos, and the instos will load up. They don't leave money on the table, and won't ignore a stock that is this undervalued.